Archive for June 7th, 2012

FDA approves XNPT Horizant. OREX initiates cardio outcomes trial. AIS to transfer to NASDAQ. ACHN CMO resigns + NBY news

Jun 07, 2012 No Comments by

GlaxoSmithKline plc (GSK) and XenoPort, Inc. (Nasdaq:XNPT) announced the FDA approved their supplemental new drug application of Horizant for the management of postherpetic neuralgia (PHN) in adults. Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that it has initiated its cardiovascular outcomes trial, called the Light-Study,  evaluating the occurrence of major adverse cardiovascular events (MACE) in patients taking Contrave, for the treatment of obesity. […]

Daily News Read more